Goley Pharmaceutical-B (01672) is included in the Hang Seng Composite Index and is expected to become the standard for Hong Kong stocks

Zhitong Finance App learned that on August 21, Hang Seng Index Company announced the results of the Hang Seng Index series quarterly review results up to June 30, 2026. Among them, Goli Pharmaceutical-B (01672) was included in the Hang Seng Composite Index. Changes in the Hang Seng Composite Index will be implemented after the market closes on September 4 (Friday) and will take effect on September 7 (Monday). At that time, the Shanghai and Shenzhen Stock Exchange will adjust the scope of investment targets of Hong Kong Stock Connect accordingly. Cully Pharmaceuticals is likely to be transferred to the Hong Kong Stock Connect because it meets a range of standards including market value and liquidity.

Goli Pharmaceuticals recently announced that after receiving approval from the US Food and Drug Administration (FDA) New Drug Clinical Trial Application (IND), it has initiated two phase I studies to treat obesity in the US: monthly to quarterly new-generation pancreatic agonist polypeptide ASC36, and ASC36 and GLP-1R/GIPR dual-target agonist polypeptide ASC35, a subcutaneous fixed dose combination (FDC) monthly injection ASC36_35FDC.